Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4057560 | 0.89 | TYMS (0.43) | TYMSCYP19A1CASP1CASP7HSD17B10 | |
| SCHEMBL16559372 | 0.83 | CASP1 (0.55) | TYMSCASP1CASP7HSD17B10TDP1 | |
| SCHEMBL4054048 | 0.83 | CYP19A1 (0.59) | CYP19A1TDP1L3MBTL1MAPK14MAOB | |
| SCHEMBL13771200 | 0.80 | CYP19A1 (0.41) | CYP19A1TDP1L3MBTL1MAPK14MAOB | |
| SCHEMBL4062450 | 0.78 | CES1 (0.61) | CYP19A1TDP1L3MBTL1MAOBALDH1A1 | |
| SCHEMBL5655558 | 0.78 | TDP1 (0.64) | TYMSCASP1CASP7HSD17B10TDP1 | |
| SCHEMBL4053805 | 0.77 | MAPT (0.49) | HSD17B10TDP1ALDH1A1NPC1CYP3A4 | |
| SCHEMBL4062549 | 0.73 | CYP19A1 (0.59) | TYMSCYP19A1MAPK14MAOBMAOA | |
| SCHEMBL10415974 | 0.73 | MAPK14 (0.53) | TYMSCASP1CASP7HSD17B10TDP1 | |
| SCHEMBL28395740 | 0.72 | RAB9A (0.55) | CASP1CASP7HSD17B10TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557212-B2 | Tricyclic derivatives as LTD4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-07-07 | — | — | US | disclosed |
| US-7557212-B2 | Tricyclic derivatives as LTD4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-07-07 | — | — | US | disclosed |
| US-7557212-B2 | Tricyclic derivatives as LTD4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-07-07 | — | — | US | disclosed |
| EP-1560834-B1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | ALMIRALL LAB (ES) | 2008-06-25 | — | — | EP | disclosed |
| US-20060116363-A1 | Tricyclic derivatives as ltd4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-06-01 | — | — | US | disclosed |
| EP-1560834-A1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004043966-A1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | ALMIRALL PRODESFARMA S.A. (ES) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116363-A1 | Tricyclic derivatives as ltd4 antagonists | LTA4H, LTC4S, LTB4R2 | TYMS 906/4885CYP19A1 1505/4885CASP1 1813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.